Published in Hypoxia (Auckl) on December 11, 2015
AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1α stabilization. Cancer Lett (2016) 0.76
Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. Biomedicines (2017) 0.76
Molecular mechanisms of hypoxia in cancer. Clin Transl Imaging (2017) 0.75
The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy. Oncotarget (2017) 0.75
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. Transl Oncol (2017) 0.75
MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. Oncol Lett (2017) 0.75
Drug delivery in a tumour cord model: a computational simulation. R Soc Open Sci (2017) 0.75
Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nat Commun (2017) 0.75
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev (1998) 12.48
The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol (1953) 12.04
A conserved family of prolyl-4-hydroxylases that modify HIF. Science (2001) 11.50
A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol (1992) 11.03
The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer (1955) 10.49
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene (2009) 8.01
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 6.84
Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem (2000) 6.71
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci (2012) 4.96
Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol (2009) 4.95
Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res (1991) 4.12
Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature (1998) 4.03
Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J (2008) 3.98
Molecular mechanisms of blood vessel growth. Cardiovasc Res (2001) 3.94
p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem (1999) 3.90
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest (2013) 3.55
Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int (2002) 3.40
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys (2000) 3.22
Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res (2006) 3.05
Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys (2004) 3.00
Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol (2000) 2.93
Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res (1987) 2.85
Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res (2001) 2.80
Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal (2007) 2.76
Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist (2004) 2.72
Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res (2003) 2.66
Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med (2011) 2.63
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol (2009) 2.45
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood (2012) 2.35
Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem J (2003) 2.27
The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene (2003) 2.22
Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res (2001) 2.19
Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol (2001) 2.15
Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res (1996) 2.10
Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res (1996) 2.07
Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res (1994) 2.02
Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ (2001) 2.01
Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat (2011) 1.87
Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res (1991) 1.86
Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys (1986) 1.84
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 1.84
ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett (2000) 1.81
Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells (2008) 1.78
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol (2009) 1.74
Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys (2002) 1.74
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res (2006) 1.71
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res (2008) 1.70
Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res (2005) 1.68
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene (2004) 1.67
Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66
Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem (2008) 1.60
HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A (2009) 1.59
Selective vulnerability in brain hypoxia. Crit Rev Neurobiol (1991) 1.57
Hypoxia-induced angiogenesis: good and evil. Genes Cancer (2011) 1.52
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther (2008) 1.49
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood (2010) 1.48
Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci (2000) 1.44
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood (2009) 1.39
Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res (2004) 1.38
Clinical experience with 118 brain tissue oxygen partial pressure catheter probes. Neurosurgery (1998) 1.37
Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene (2012) 1.37
Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol (1998) 1.37
Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int (2004) 1.36
Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res (2010) 1.35
Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets (2013) 1.33
Targeting the tumor microenvironment for cancer therapy. Clin Chem (2012) 1.32
Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett (2012) 1.30
Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer (2010) 1.30
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene (2013) 1.24
Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences. Strahlenther Onkol (2012) 1.24
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther (2009) 1.19
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res (2009) 1.18
HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer (2009) 1.17
Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther (2013) 1.16
Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep (2015) 1.10
Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiother Oncol (2009) 1.08
The relationship between hypoxia and angiogenesis. Semin Radiat Oncol (2004) 1.07
Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate. J Cell Biochem (2015) 1.05
Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer J (2014) 1.02
Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta (2000) 1.02
Minimal residual disease in multiple myeloma. J Clin Oncol (2013) 1.01
NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS One (2011) 1.00